SLShu Li

Shu Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Shu Li has a total of 22 co-authors. Here are the top co-authors by number of shared publications:

  • Jiayong Liu

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China

    3 shared publications
  • Zhengfu Fan

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China

    3 shared publications
  • Tian Gao

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China

    2 shared publications
  • Zhichao Tan

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China

    2 shared publications
  • Chujie Bai

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, Beijing, China

    1 shared publication
  • Chujie Bai

    Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China

    1 shared publication

Latest Publications

  • Open Access

    Lymphatic Mapping to the Inguinal Region in Patients with Lower Extremity Melanoma Undergoing Radical Inguinal Lymph Node Dissection: A Retrospective Cohort Study

    by Zhichao Tan, Yue Sun, Yunxiao Zhang, Zhengfu Fan, Chujie Bai, Shu Li, Tian Gao, Lu Zhang, Ruifeng Xue, Xinyu Wang, et al.

    Background/Objectives: The anatomical distribution of inguinal lymph node (ILN) metastases may inform research on the extent of therapeutic dissection for lower-limb melanoma. Methods: Fifty-eight patients undergoing radical inguinal lymph node dissection (rILND) were retrospectively evaluated using five anatomical zones. Zone-specific node counts were reaggregated, and exploratory binary logistic regression assessed multiple-zone involvement. Results: The cohort included 48 clinically node-positive and 10 sentinel lymph node biopsy (SLNB)-positive patients. Among 816 mapped ILNs, 149 were positive. Zone I contained 102/149 positive nodes (68.5%); within-zone positivity was 102/303 (33.7%) in zone I, 27/243 (11.1%) in zone II, 13/190 (6.8%) in zone III, 3/39 (7.7%) in zone IV, and 4/41 (9.8%) in zone V. Five patients had no positive mapped ILNs. Zone I contained the only positive node in 19/20 patients (95.0%) and was the sole involved zone in 32/33 patients with single-zone involvement (97.0%). Twenty patients had multiple-zone involvement. In a two-variable complete-case model (50 patients; 18 events), ≥3 positive ILNs remained associated with multiple-zone involvement (adjusted odds ratio, 34.80; 95% confidence interval, 5.88–206.08), whereas extranodal extension did not. Conclusions: This small, selected cohort provides preliminary pathological evidence of preferential inferior-zone involvement. It does not establish sequential spread or the oncological safety of reduced rILND. External and prospective validation are required.

  • Open Access

    The efficacy and predictive value of 99mTc-rituximab for sentinel lymph node biopsy in acral melanoma patients

    by Ruifeng Xue, Zhiyan Liu, Zhichao Tan, Yujun Cui, Chujie Bai, Shu Li, Tian Gao, Lu Zhang, Xinyu Wang, Zhengfu Fan, et al.

    We sought to evaluate the efficacy and predictive value of 99mTc-rituximab as a tracer for sentinel lymph node biopsy (SLNB) in acral melanoma (AM) patient

  • Open Access

    AZGP1 inhibits soft tissue sarcoma cells invasion and migration

    by Jiayong Liu, Haibo Han, Zhengfu Fan, Marc El Beaino, Zhiwei Fang, Shu Li, Jiafu Ji

    One of the major challenges in soft tissue sarcomas is to identify factors that predict metastasis. AZGP1 is a potential biomarker of cancer progression, but its value in soft tissue sarcomas remains unknown. The aim of this study is to determine the expression level of AZGP1 in soft tissue sarcomas, and to analyze its influence on tumor progression. AZGP1 immunohistochemistry (IHC) and RT-PCR were performed in 86 patients with soft tissue sarcomas. The relationships between AZGP1 levels and clinicopathologic features were analyzed. In vitro experiments were performed using fibrosarcoma (HT1080), rhabdomyosarcoma (RD) and synovial sarcoma (SW982) cell lines to corroborate our findings. We used lentiviral over-expression and knockdown assays to examine how changes of AZGP1 expressions might affect cellular migration and invasion. The quantitative RT-PCR results showed that AZGP1 expression was negatively correlated with metastasis and overall survival in soft tissue sarcomas (p < 0.05). Immunohistochemical staining showed lower expression of AZGP1 in patients with metastasis than in those without. Kaplan-Meier survival analysis showed that patients with low expression of AZGP1 had shorter overall (p = 0.056) and metastasis-free survivals (p = 0.038). These findings were corroborated by our in vitro experiments. Over-expression of AZGP1 significantly decreased RD cellular migration and invasion by 64% and 78%, respectively. HT1080 cells migration was inhibited by 2-fold, whereas their invasion was repressed by 7-fold after AZGP1 knockdown. Our study reveals that reduced AZGP1 expression correlates with in vitro cellular migration and invasion. In vivo, it is associated with higher metastatic risk and shorter survival in patients with soft tissue sarcomas.